Onasemnogene abeparvovec 20TVG/mL (TVG = Tera Vector Genomes; equivalent to 2 x 10^13 vector genomes per mL); Onasemnogene abeparvovec 20TVG/mL (TVG = Tera Vector Genomes; equivalent to 2 x 10^13 vector genomes per mL) - rizultati

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zolgensma

novartis europharm limited - onasemnogene abeparvovec - atrofija muskolari, spinali - mediċini oħra għal disturbi fis-sistema muskoloskeletali - zolgensma huwa indikat għall-kura ta': pazjenti b'5q spinali-atrofija muskolari (sma) bil-bi-allelic mutazzjoni fil-smn1 tal-ġeni u l-dijanjosi klinika tal-sma tat-tip 1, orpatients mal-5q sma bil-bi-allelic mutazzjoni fil-smn1-ġeni u sa 3 kopji ta'l-smn2 ġene.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

evrysdi

roche registration gmbh - risdiplam - atrofija muskolari, spinali - mediċini oħra għal disturbi fis-sistema muskoloskeletali - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.